Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement by Dr Jose Dominguez.

Citation:

Jose Dominguez, Martin J. Boeree, Dumitru Chesov, Francesca Conradie, Vivian Cox, Keertan Dheda, Andrii Dudnyk, Maha R. Farhat, Sebastien Gagneux, Martin P. Grobusch, Matthias Groeschel, Lorenzo Guglielmetti, Irina Kontsevaya, Berit Lange, Frank van Leth, Christian Lienhardt, Anna M. Mandalakas, Florian Maurer, Matthias Merker, Paolo Miotto, Barbara Molina-Moya, Florence Morel, Stefan Niemann, Nicolas Veziris, Andrew Whitelaw, Charles R. Horsburgh, and Christoph Lange. 2/28/2023. “Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement by Dr Jose Dominguez.” The Lancet Infectious Diseases. Publisher's Version
Last updated on 03/02/2023